Atopobium Parvulum

This bacterium can feed into hydrogen sulfide chemistry in the colon. It makes that gas by breaking down the sulfur-containing amino acid cysteine, a different route from the sulfate-reducing bacteria that get most of the attention. In small amounts, hydrogen sulfide is part of normal gut signaling. At higher local levels, especially when the gut lining is already inflamed or less able to clear it, it can loosen the protective mucus layer and stress the cells lining the intestine.

That is why a stool result can be interesting. It is a research marker, not a diagnosis. There is no validated cutoff, and stool may not match the bacteria sitting against the gut wall. If you have ongoing gut symptoms and a stool panel includes this species, read it alongside calprotectin, pathogens, blood, and the rest of the panel.

What the Test Actually Measures

The test measures bacterial DNA from a stool specimen. Depending on the lab, it may be reported from targeted PCR, 16S sequencing, or shotgun sequencing, and the result is usually a share of total bacteria rather than a direct count of living cells.

You are measuring an organism, not a substance made by your body. The result mainly reflects how much of this species' DNA was present in the sampled stool, so collection, DNA extraction, sequencing depth, and the lab's reference database matter.

This species has been renamed Lancefieldella parvula. Many papers and lab reports still use Atopobium parvulum. Same organism, different naming era.

Crohn's Disease and Intestinal Inflammation

The strongest disease-specific human evidence is still from gut-lining-adjacent samples in children with new Crohn's disease, not from consumer stool panels. Researchers sampled the mucosa-luminal interface during colonoscopy. That is the layer where bacteria meet the gut lining.

In those children, this organism was more abundant than in controls, and higher abundance tracked with worse measured inflammation. That link with inflammation severity showed up in Crohn's disease but not in ulcerative colitis, which is part of why the authors argued it was not simply a byproduct of inflammation. Higher abundance also tracked with lower output of mitochondrial proteins in the lining cells, including the enzymes that clear hydrogen sulfide. Mitochondria are the parts of cells that turn food into usable energy.

In the same study, this species was the central hub in a network of hydrogen-sulfide producers. That does not prove it caused Crohn's disease. It does make it more than a random bystander in that dataset.

There is also causal evidence, though not in people. In colitis-prone mice that already carried a normal gut community, adding this bacterium worsened colitis. In germ-free mice carrying this species and nothing else, it did not cause significant colitis, so the damage depended on the rest of the community being there. Bismuth subsalicylate, which binds hydrogen sulfide, lowered the colitis scores, although the authors noted that some of that benefit could come from bismuth's antibacterial action rather than sulfide binding alone. That is causal evidence in mice. It is not evidence that bismuth treats this finding in people.

Read your own result with that split in mind. A high stool number is a signal about a sulfur-linked bacterial pattern. It is not a Crohn's diagnosis, and a low number does not rule out inflammatory bowel disease.

Gut Symptoms Without a Diagnosis

In APECED, a rare inherited autoimmune condition, a small stool study of 15 patients and 15 controls found an altered gut bacterial community that tracked with more severe digestive symptoms. The clearest reported signal was enrichment of biofilm-forming bacteria, not this species specifically.

That is indirect, genus-level support for the broader pattern. When the stool community tilts toward biofilm-forming and mouth-associated bacteria, the gut is often not in its quiet state.

Why It Shows Up on Oral Panels Too

This bacterium is at home in the mouth. Finding it in stool can mean at least two things: it may be part of a true colon community, or it may reflect mouth bacteria repeatedly entering and surviving the gut.

A 2025 meta-analysis of 22,710 human microbiome samples built an oral enrichment score for stool. People with many different diseases tended to have more mouth-type bacteria in stool than healthy controls, a pattern that held in 29 of 30 case-control datasets. That was a community-level signal.

The clearest single-species exception comes from early colorectal cancer research. In a Japanese study of 616 participants, this species, alongside Actinomyces odontolyticus, was elevated specifically in people with multiple polypoid adenomas and with stage 0 intramucosal carcinoma, confirmed with a separate counting method. It again sat at the center of a hydrogen-sulfide-producing network. That is a stage-specific association in one population, not a validated screen, and a large 2026 analysis found gut bacterial associations with precancerous growths were weak and inconsistent once other factors were accounted for.

No comparable evidence shows that this single species predicts diabetes on its own. Treat a high result as one line in a larger pattern of oral-to-gut migration and gut irritation, not a disease risk score.

What a Single Reading Can and Cannot Tell You

No published clinical reference range exists for this organism. Different labs use different DNA targets, different normalization methods, and different proprietary percentile bands. A number from one lab is not directly comparable to a number from another.

Several things can shift a single reading in ways that have little to do with your usual gut state:

• Recent antibiotics: antibiotics can reshape stool communities and can make oral and stool profiles unstable, especially in hospitalized or recently treated people. A sample during or soon after antibiotics is a poor baseline.
• Which lab and which method: broad sequencing, targeted PCR, and shotgun sequencing can disagree because they use different targets and reference databases.
• Stool versus gut lining: the main Crohn's evidence came from gut-lining-adjacent samples. Stool is easier to collect, but it is less direct.
• Smoking, and possibly pregnancy: adolescent smokers carried more of this species in the mouth in a study of 98 smokers and 98 matched non-smokers. A separate saliva study reported higher levels in late pregnancy, a weaker and less replicated finding. Neither study measured stool.
• Acute gut disruption: diarrhea, bowel prep, food poisoning, and major illness can shift the whole stool community for a while. Wait until you are back to baseline.

Why the Trend Beats Any Single Number

Since there is no validated threshold, a repeat result is mostly useful as a within-person comparison. Use the same lab. A number from one lab should not be stitched to a number from another.

The gut microbiome is not random noise. In adults followed for up to six years, stool and oral communities were more stable and more individual than skin or nasal communities. That supports serial tracking, but it does not validate a treatment target for this one species.

No study has shown that any diet, probiotic, supplement, or dental treatment reliably moves this specific organism in stool. If your number falls after you change something, that is your own data point, not established cause and effect.

How to Read It With Companion Markers

This number means little alone and more in context. Fecal calprotectin is the companion result that matters most, because it is a direct marker of gut-wall inflammation.

Separate three patterns. High count with normal calprotectin and no symptoms is a tracking clue. High count with elevated calprotectin, blood in stool, weight loss, or persistent diarrhea deserves a gastroenterology workup. High count in someone with known inflammatory bowel disease is context for a specialist, not a reason to change treatment on your own.

If your result is high and you have gum disease, bleeding gums, or years since your last dental care, deal with the mouth first. Periodontal therapy changed both oral and gut bacterial communities within three months in one study, though it did not report this species.

What this result does not justify is antibiotics. There is no evidence that treating this species improves symptoms, inflammation, or cancer risk, and no regimen has been established. A drug aimed at one commensal can disturb the whole community.